Key Insights

Highlights

Success Rate

90% trial completion (above average)

Published Results

14 trials with published results (52%)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 5/100

Termination Rate

7.4%

2 terminated out of 27 trials

Success Rate

90.0%

+3.5% vs benchmark

Late-Stage Pipeline

26%

7 trials in Phase 3/4

Results Transparency

78%

14 of 18 completed with results

Key Signals

14 with results90% success

Data Visualizations

Phase Distribution

24Total
Not Applicable (10)
P 2 (7)
P 3 (6)
P 4 (1)

Trial Status

Completed18
Recruiting3
Terminated2
Unknown2
Enrolling By Invitation1
Withdrawn1

Trial Success Rate

90.0%

Benchmark: 86.5%

Based on 18 completed trials

Clinical Trials (27)

Showing 20 of 20 trials
NCT06219707Not ApplicableRecruitingPrimary

Electro-acupuncture for Irritable Bowel Syndrome With Constipation

NCT05796388Not ApplicableRecruitingPrimary

A Study of Virtual Reality and Linaclotide for IBS-C

NCT04166058Phase 3CompletedPrimary

Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C

NCT03596905Phase 2CompletedPrimary

Efficacy and Safety of Plecanatide in Children 6 to <18 Years With Irritable Bowel Syndrome With Constipation (IBS-C)

NCT05519683Phase 2RecruitingPrimary

Home Transcutaneous Electrical Acustimulation (TEA)

NCT07103772Not ApplicableEnrolling By Invitation

Effect of Consuming a Nutraceutical Composition on Signs and Symptoms in Adult Patients With Irritable Bowel Syndrome

NCT04214470Withdrawn

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in IBS

NCT04026113Phase 3Completed

Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC)

NCT04968652CompletedPrimary

IBS-C Questionnaire Study

NCT04997057Not ApplicableCompletedPrimary

A Multistrain Probiotic in Patients With Irritable Bowel Syndrome With Predominant Constipation

NCT05164861Not ApplicableCompletedPrimary

Safety and Efficacy of Non-alcoholic Beverage Based on Kombucha in Patients With Constipations

NCT05646186Not ApplicableUnknown

Personalized Dietary Intervention Based on Microbiome Analysis vs FODMAP Diet for Irritable Bowel Syndrome

NCT04132804Not ApplicableCompletedPrimary

Effect of Tai Chi as Treatment for IBS-C

NCT03763175Phase 2TerminatedPrimary

Efficacy and Safety of SYN-010 in IBS-C

NCT02559817Phase 2TerminatedPrimary

A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation

NCT04647045Not ApplicableCompletedPrimary

An Evaluation of Cultured Milk Drink on Immune Status of Patients With Irritable Bowel Syndrome: Constipation Predominant

NCT04484467Not ApplicableCompleted

Efficacy and Safety of a Food Supplement With Standardized Menthol, Limonene, and Gingerol Content in Patients With Irritable Bowel Syndrome

NCT02559206Phase 2CompletedPrimary

Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

NCT00380250Phase 3CompletedPrimary

Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation

NCT02590432Phase 4CompletedPrimary

An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to Adult Participants With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation

Scroll to load more

Research Network

Activity Timeline